Behavioural, educational and respiratory outcomes of antenatal betamethasone for term caesarean section (ASTECS trial)
- Peter Roy Stutchfield1,
- Rhiannon Whitaker2,
- Angela E Gliddon2,
- Lucie Hobson3,
- Sailesh Kotecha4,
- Iolo J M Doull5
- 1Department of Paediatrics, Betsi Cadwaladr University Health Board, Glan Clwyd Hospital, Rhyl, UK
- 2NWORTH CTU, Bangor University, Bangor, UK
- 3NISCHR CRC, Rhyl, UK
- 4Department of Child Health, Cardiff University School of Medicine, Cardiff, UK
- 5Department of Paediatric Respiratory Medicine, Children's Hospital for Wales, Cardiff, UK
- Correspondence to Dr Peter Roy Stutchfield, Department of Paediatrics, Betsi Cadwaladr University Health Board, Glan Clwyd Hospital, Rhyl, Denbighshire, LL18 5UJ, UK;
- Received 5 October 2012
- Accepted 17 January 2013
- Published Online First 19 February 2013
Objectives To determine whether antenatal betamethasone prior to elective term caesarean section (CS) affects long term behavioural, cognitive or developmental outcome, and whether the risk of asthma or atopic disease is reduced.
Design A questionnaire based follow-up of a multicentre randomised controlled trial (Antenatal Steroids for Term Elective Caesarean Section, BMJ 2005).
Setting Four UK study centres from the original trial.
Participants 862 participants from the four largest recruiting centres, 92% of the original study. 824 (96%) were traced and 799 (93%) were successfully contacted. Fifty-one percent (407/799) completed and returned the questionnaire. The children were aged 8–15 years (median 12.2 years, 52% girls). 386 gave consent to contact schools with 352 (91%) reports received.
Main outcome measures Questionnaires including a strengths and difficulties questionnaire, International Study of Asthma and Allergies in Childhood, general health and school performance.
Results There were no significant differences between children whose mothers received betamethasone and controls for the mean total strengths and difficulties questionnaire scores and subscores for hyperactivity, emotional symptoms, prosocial behaviour, conduct or peer problems. 25 (12%) children whose mothers received betamethasone had reported learning difficulties compared with 27 (14%) control children. The proportion of children who achieved standard assessment tests KS2 exams level 4 or above for mathematics, English or science was similar as were the rates of ever reported wheeze (30% vs 30%), asthma (24% vs 21%), eczema (34% vs 37%) and hay fever (25% vs 27%).
Conclusions Antenatal betamethasone did not result in any adverse outcomes or reduction in asthma or atopy. It should be considered for elective CS at 37–38 weeks of gestation.
Trial registration: Original trial was preregistration, the trial publication is BMJ. 2005 Sep 24;331(7518):662.
What is already known on this topic
Antenatal betamethasone reduces respiratory morbidity in term babies delivered by elective caesarean section by 50%.
A single course of antenatal steroid has no adverse effect on subsequent physical growth and neurological or cognitive development of babies born before 34 weeks gestation.
Antenatal steroids lead to upregulation of pulmonary epithelial sodium channel genes with a switch from lung fluid secretion to fluid absorption and increased surfactant production.
What this study adds
No adverse effect was seen on health, behaviour and academic achievement of children born following a single course of antenatal betamethasone at term.
Antenatal betamethasone did not reduce the prevalence of asthma and allergy following elective caesarean section.
Birth by caesarean section (CS) in westernised countries has increased significantly over the last three decades1 increasing from 16% in 1995 to 25% in 2007 in the UK,2 ,3 and from 20% in 1996 to 31% in 2006 in the USA.4 However elective CS at term is associated with significant neonatal morbidity5–7 respiratory distress syndrome (RDS), transient tachypnoea of the newborn (TTN), need for mechanical ventilation8 and longer term conditions including 20% increased risk of asthma,9 type 1 diabetes mellitus,10 with a twofold increased risk of atopy.11
The well-established benefits of antenatal corticosteroids prompted the Antenatal Steroids for Term Elective Caesarean Section (ASTECS) study12 which demonstrated decreased risk of TTN (0.040 vs 0.021; relative risk (RR) 0.54, 95% CI 0.26 to 1.12) and RDS (0.011 vs 0.002; RR 0.21, 95% CI 0.03 to 1.32). The predicted probability of admission to a neonatal unit with respiratory distress at 37 weeks was 11.4% in the control group and 5.2% in the treatment group, at 38 weeks 6.2% and 2.8%, and at 39 weeks 1.5% and 0.6%, respectively, confirming a 50% reduction in respiratory morbidity up to 39 weeks gestation.
Concerns have been raised about the potential long term effects of administering exogenous steroids before elective CS.13 A Cochrane review14 and the evidence based guideline of the Royal College of Obstetricians and Gynaecologists15 concluded that a single course of antenatal steroid has no adverse effect on subsequent physical growth and neurological or cognitive development. In contrast, repeated courses of antenatal or postnatal steroids to facilitate extubation from mechanical ventilation show conflicting results with reported increases in cerebral palsy and behavioural changes.16–18
We hypothesised that the short course of antenatal steroids administered prior to an elective CS would not result in long term neurological or cognitive development effects, but might, through the decreased risk of RDS and TTN, decrease the risk of development of asthma and atopic diseases.
ASTECS was a randomised open label trial of two intramuscular doses of 12 mg betamethasone separated by 24 h within 48 h of delivery, compared with usual treatment without antenatal steroids in pregnant women undergoing elective CS at term. ASTECS was conducted between 1995 and 2002. ASTECS-2 is a follow-up study of the children aged 8–15 years. No studies have been reported using antenatal steroids at term.19
Of the 998 women entered into ASTECS, logistical considerations dictated that we restrict the follow-up study ASTECS-2 to those delivered at the four largest recruiting centres. Tracing was performed using information from the original study, local child health registers and the National Health Service (NHS) demographic tracking system. Ethics approval was obtained from South East Wales Research Ethics Committee.
Participants were sent study information including questionnaires and consent forms and asked for permission to contact their schools. Study numbers and return rates are shown in the CONSORT diagram, figure 1. The original trial blinded allocation was reused in the current study.
The questionnaire was based on the International Study of Asthma and Allergies in Childhood20 and supplemented with further questions on the child's medical history, hospital admissions, attainment in school key stages 1 and 2 national standard assessment tests (SATs) and the child's strengths and difficulties questionnaire (SDQ) which consists of 25 questions providing measures in five dimensions—hyperactivity, emotional symptoms, conduct problems, peer problems and prosocial behaviour.21 The four difficulties scores are combined to create the total SDQ score. Normal total SDQ scores lie between 0 and 13, borderline between 14 and 16 and abnormal 17+. As we were investigating the potential negative effects of betamethasone, a one-sided test was applied to each of these subscales and the total difficulties score. The school was asked to confirm SATs key stages 1 and 2 results and to give data on general progress, behavioural characteristics and special educational needs.
The principal analyses are descriptive and one-sided tests were used (χ2 tests for categorical comparisons and either t-tests or Mann Whitney tests for scale variables) with 5% significance reported.
We followed up all 862 participants from the four largest recruiting centres, 92% of 942 of the original study from 10 centres (figure 1), and 824 (96%) were traced—25 communications were returned as ‘unknown at this address’. Of 799 successfully contacted, 51% (407) returned the completed questionnaires. The children were aged 8–15 years with a median age of 12.2 years of which 52% were girls. Of the 407 recruited, 386 parents consented to contacting schools, and responses were received for 352 children (figure 2).
Representativeness of the four centres sampled
The 942 mothers in the original study had a mean age of 30.8 (SD±5.2) years, 199 (21%) reported being smokers and 102 (11%) reported asthma. The babies had a mean gestation of 269 (SD±6.6) days and birth weight of 3290 (SD±470) g. Of these babies 58 (6%) were admitted to the special care baby unit (SCBU) with 35 (4%) having respiratory difficulties. A comparison with the sample drawn from the four centres included in ASTECS-2 revealed no significant differences in either maternal or child characteristics except that the centres that were followed up admitted a smaller proportion of babies (6%) to SCBU than the centres that were not followed up (13%) (p=0.01).
Representativeness of responders to the study
Study respondents were slightly older (31.9(SD±4.9) years vs 29.7(SD±5.2) years, p<0.01), more likely to have been non-smokers (84% vs 75%, p<0.01) and more likely to have had a baby admitted to SCBU (7% vs 4%, p=0.06) than non-respondents. Rates of asthma, emergency CS, gestational age and birth weight were similar. Infants of respondent mothers were more likely to have been admitted to SCBU with respiratory difficulties than those whose mothers did not respond (5% vs 2%, p=0.01).
Comparison of treatment and control demographic data
Table 1 gives the original ASTECS demographics for the respondents, comparing the betamethasone and control groups. Both groups had similar participant (mother) demographic profile and the babies had similar birth weights and gestational ages. As in the original ASTECS study, ASTECS-2 control group respondents had a higher proportion of children admitted to SCBU (21 (11%) compared with 8 (4%) in the treatment group, p<0.01) with a higher proportion of children admitted to SCBU with respiratory distress, (17 (9%) compared with 5 (2%) in the treatment group, p<0.01).
The mean SDQ scores for the strengths and difficulties subscales were similar in both groups (table 2). None of the differences reached statistical significance. There were no significant differences between the two groups in the proportion of children requiring additional help in school, 34 (18%) of those mothers who received betamethasone compared with 22 (13.3%) controls χ2(1)=1.49, p=0.22 who did not.
Of the 407 children followed up, 305 were 11 years or older and would have received a KS2 level evaluation; schools reported data for 266 (87%) children. There were no significant differences between groups in the levels attained at KS2 with 88% achieving level 4 or above in mathematics in the control group versus 86% in the betamethasone group, in science 94% in the control group versus 91% in the betamethasone group and in English 93% in the control group versus 87% in the betamethasone group. KS1 school reports were received for 74 of the 102 children who were too young to have a KS2 assessment. There were no significant differences noted in the number of children reaching levels 2 or 3 between betamethasone and control children. Schools were asked to report which quartile of ability they perceived each child to be in. The difference between the groups did reach significance. Twenty-five (12%) children whose mothers received betamethasone had reported learning difficulties compared with 27 (14%) control children. Dyslexia was the most common learning difficulty reported followed by attention deficit disorder (ADHD) (nine controls and seven treatment children with dyslexia, four controls and three treatment children with ADHD). Two children in the betamethasone group had severe learning difficulties; one had X linked mental retardation and the other global developmental delay with dysmorphic features. One child in the control group with severe learning difficulties had Down's syndrome. Two children in each arm had Asperger's syndrome and autism was noted in two treatment group and two control group children.
There were no significant differences between the two groups in any parent reported measures of overall health (table 3). Rates of medical problems reported, hospital admissions ever, learning difficulties, movement problems and numbers of children on medications were similar between the two groups. There was no significant difference between the two groups in the rates of asthma, whether measured by wheeze ever, wheeze in the last year, use of inhalers or having asthma, or in reported eczema or hay fever. There was no significant difference in hospital admission rates for respiratory or non-respiratory causes with fewer reported hospitalisations as a result of accidental injury in those whose mothers had received betamethasone. Only one (control) child was diagnosed with diabetes.
We extended our analysis of the results of the parent questionnaire to consider the health of those children who had been admitted to SCBU after birth. As the study is not powered to detect differences in such small numbers of children, we have presented the results in table 4 without applying statistical testing.
We found no difference in behavioural characteristics between children whose mothers received betamethasone and those who did not as determined by the Strengths and Difficulties questionnaire (SDQ). The results of the SATs key stages 1 and 2 demonstrated that the treatment and control populations did not differ in academic achievement, with results comparable with the normal population and within government targets. No children were reported to have cerebral palsy or neurological disability. There was no evidence that general health was adversely affected with no significant difference in the number of children admitted to hospital with infections and accidental injury. Antenatal betamethasone did not affect the number of children who developed asthma or atopic disease.
This is the first published study to assess the long-term outcome for children whose mothers received a single course of betamethasone antenatally before elective CS at term. For logistical reasons only children whose mothers were recruited at the four main centres were identified for the follow-up study.12 Demographic data of these mothers and children was comparable with that of the whole group.
A primary strength of this study was the children were more than 8 years old—an age when physical, behavioural and learning difficulties are more likely to be evident. There are a number of limitations, however. Although we achieved a 51% response rate to those who were traced, the total number of children in the control and betamethasone groups (190 vs 217) is small. With the time delay between the initial recruitment to the ASTECS study and the start of the follow-up study, ASTECS-2, not all mothers could be traced. Mothers who had no recollection of the ASTECS trial, predominantly from the control group, were less likely to respond to the initial letter potentially leading to bias. Follow-up phone calls of all who did not respond allowed the study to be discussed with an effective increase in recruitment. The trial allocation remained blinded throughout the process.
Responses to the questionnaires depended on the mothers’ recall and assessment. We did not refer to general practitioner or hospital records and teachers were not asked to complete SDQ questionnaires. However large community studies suggest that parents and teachers provide information of roughly equal predictive value. Behaviour determined through the SDQ has been well validated,22 and there was no difference between the two groups although slightly more children in the betamethasone group had scores in the abnormal range for hyperactivity and emotional symptoms. This may indicate a difference in behaviour but comes from only one source of information. The SDQ is a screening tool to identify those at increased risk but clinical assessment, teacher's reports and psychological testing are necessary to identify a problem. Normative SDQ data for Britain from 10 438 children 5–15 years old shows 16% of 5–10 years old and 12.9% of 11–15 years old children had a hyperactivity health score in the abnormal range.23 For the emotional health symptoms score the corresponding figures are 10.6% and 12.2%, respectively. There were more children reported to have ADHD, dyslexia and autism in the control group.
Academic progress, including details of learning difficulties requiring additional support, was substantiated by the questionnaire to the schools. However not all mothers or young people agreed to the school being contacted, potentially introducing bias, although this could affect both groups. We obtained information on key stages 1 and 2 SATs for those attending schools in England. SATs were abolished for pupils resident in Wales in 2004 with the grade achieved derived by teacher assessment. The difference between the school assessments recorded in quartiles of academic ability, appeared a discordant finding. Ideally standardised, age-appropriate, cognitive and psychological assessments would have been undertaken on all in the follow-up study but this was not possible.
Follow-up studies reporting outcome up to 31 years after a single course of antenatal steroid given to mothers delivering before 34 weeks gestation have not shown adverse effect on physical growth and neurological or cognitive development.14 ,15 ,24 However outcome studies following repeated courses of antenatal steroids from 24 weeks gestation, or high doses used postnatally to reduce chronic lung disease, have shown conflicting results with increase in cerebral palsy and behavioural changes reported.16–18 ,25 With three or more courses of antenatal steroid, an increase in rates of aggressive/destructive, distractible, and hyperkinetic behaviour at 3 years and 6 years are reported.25 The current evidence suggests that the very immature brain is vulnerable when exposed to high doses of corticosteroid for prolonged periods either antenatally or postnatally. As with the preterm infant, our findings suggest that there were no adverse consequences of a single course of antenatal betamethasone at term gestation.
Dalziel et al reported no difference in lung function at 30 years between 181 betamethasone-exposed and 202 placebo-exposed participants whose mothers were randomised at 24–36 weeks gestation to receive a single course betamethasone.26 The prevalence of asthma, eczema and hay fever was similar between groups, and comparable with the International Study of Asthma and Allergies in Childhood phase 3 studies conducted between 1999 and 2004.27 Our findings suggest that antenatal steroids do not significantly affect the rate of development of atopic disease.
Our follow-up study has provided no reason to change our original recommendations that delivery by elective CS should be delayed until the 39th week wherever possible to reduce the risk of respiratory morbidity.12 When it is necessary to deliver by prelabour CS at 37 weeks or 38 weeks, parents can be reassured that the administration of a single course of antenatal betamethasone is not only beneficial in the short term, but does not have any adverse long term consequences.
The authors would like to thank Kirsty Macguire, Darren Baker, Huw Roberts, Debbie Skelhorn, Sarah Evans, Sarah Kotecha, Professor Ben Shaw, Dr Jim Turner, Haydn and Rachel Sigsworth, Dr Mathew Ellis, Phil Shrimpton, Dr Jonathan Cox, Lesley Poole, Dr Eduardo Moya, Barry Clarke and Richard Walker for their contributions to the smooth running and success of the research. Special thanks are due to all the parents and schools who took time and responded to the questionnaires.
Contributors All authors contributed to the design of the protocol and have contributed to, read and commented upon successive drafts of this paper. Additionally: PRS is the consultant paediatrician and neonatologist who developed the protocol, and initiated and coordinated the original ASTEC trial. He contacted local Principle Investigator and arranged contact details through local child health managers. He contacted mothers and schools to aid recruitment, supervised collection, validation and analysis of data. He is the clinical guarantor. RW was the trial statistician for the original ASTECS study who designed and oversaw the data collection, supervised the ethical submission, developed the analysis plan and analysed this study. She is the statistical guarantor. AEG is the study's manager who submitted the ethical approval, was responsible for trial management and clinical governance, arranged patient representation in the study, assisted with analysis of the data and updated literature searches. LH is the study research nurse who wrote patient information sheets and consent forms, organised distribution of maternal and school questionnaires, coordinated the collection and validation of the data and ensured effective management of the study. SK is a professor of child health who was involved in the development and management of this follow-up study, providing advice and guidance throughout. IJMD is a consultant respiratory paediatrician who was instrumental in the development of the protocol to compare prevalence of asthma. He has been involved in the management of this study, providing advice and guidance.
Funding This study was partially funded by the North Wales Small Grant Committee and Welsh Children and Young People's Research Network (CYPRN).
Competing interests All authors have the support of Betsi Cadwaladr University Health Board for the submitted work but no other competing interest.
Ethics approval South East Wales Research Ethics Committee.
Patient consent Obtained.
Provenance and peer review Commissioned; externally peer reviewed.
Data sharing statement If further information on the original ASTECS study or the current follow-up study is required Dr Peter Stutchfield the Chief Investigator for both studies can be contacted at firstname.lastname@example.org
Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/3.0/ and http://creativecommons.org/licenses/by-nc/3.0/legalcode